Literature DB >> 16233954

Relaxin-induced reduction of infarct size in male rats receiving MCAO is dependent on nitric oxide synthesis and not estrogenic mechanisms.

Brian C Wilson1, Barry Connell, Tarek M Saleh.   

Abstract

Relaxins are members of the insulin peptide superfamily. Previous evidence has shown that relaxin pretreatment reduces cortical infarct size in anesthetized, male rats receiving permanent middle cerebral artery occlusion (MCAO). Therefore, the current study was designed to determine if estrogenic mechanisms or nitric oxide production are involved in mediating this relaxin-induced neuroprotection. In separate groups of rats (n=4-6), the following drugs were injected directly into the cortex 30 min prior to MCAO: (a) relaxin, (b) relaxin and estrogen, and (c) relaxin and an estrogen receptor antagonist (ICI 182,780). To investigate the involvement of nitric oxide, relaxin or relaxin and an inhibitor of endothelial nitric oxide synthase (L-NIO) were injected i.v. 30 min prior to MCAO. Saline-treated rats (both intracortical (i.c.) and intravenously (i.v.)) served as controls. Brains were harvested 4h post stroke, coronally sectioned using a brain matrix and stained using 2,3,5-triphenoltetrazolium chloride (TTC). Digital photographs were taken of brain sections and the ratio comparing the area of the infarct to the area of the ipsilateral hemisphere was calculated. Mean ratios were compared using ANOVA and Tukey's test. Intracortical and intravenous relaxin pretreatment significantly reduced the infarct area in the cortex by 33.7 and 58.6%, respectively compared to saline-treated controls. This effect was not dependent on an interaction with estrogenic receptors as co-injection of relaxin and ICI 182,780 did not reverse this effect. However, inhibition of nitric oxide synthase significantly reduced the relaxin-mediated neuroprotection suggesting that relaxin may induce the endothelin-NOS cascade in cerebral vasculature causing vasodilation and improved perfusion of neural tissue.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16233954     DOI: 10.1016/j.neulet.2005.09.059

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  12 in total

Review 1.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 2.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

3.  Relaxin peptide hormones are protective during the early stages of ischemic stroke in male rats.

Authors:  Lindsay H Bergeron; Jordan M Willcox; Faisal J Alibhai; Barry J Connell; Tarek M Saleh; Brian C Wilson; Alastair J S Summerlee
Journal:  Endocrinology       Date:  2014-12-02       Impact factor: 4.736

Review 4.  Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.

Authors:  Javier Díez; Luis M Ruilope
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2015-11-26

5.  Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.

Authors:  Gerasimos Filippatos; Dimitrios Farmakis; Marco Metra; Gad Cotter; Beth A Davison; G Michael Felker; Barry H Greenberg; Tsushung A Hua; Peter S Pang; Piotr Ponikowski; Min Qian; Thomas A Severin; Adriaan A Voors; John R Teerlink
Journal:  Clin Res Cardiol       Date:  2017-02-01       Impact factor: 5.460

Review 6.  The relaxin peptide family - potential future hope for neuroprotective therapy? A short review.

Authors:  Marius Nistor; Martin Schmidt; René Schiffner
Journal:  Neural Regen Res       Date:  2018-03       Impact factor: 5.135

Review 7.  Hormone Replacement Therapy: Would it be Possible to Replicate a Functional Ovary?

Authors:  Swati Agarwal; Faisal A Alzahrani; Asif Ahmed
Journal:  Int J Mol Sci       Date:  2018-10-14       Impact factor: 5.923

8.  Protective effect of hypoxic and ischemic preconditioning in rat brain local ischemia.

Authors:  N S Samoilenkova; S A Gavrilova; V B Koshelev
Journal:  Dokl Biol Sci       Date:  2007 May-Jun

Review 9.  Relaxin as a natural agent for vascular health.

Authors:  Daniele Bani
Journal:  Vasc Health Risk Manag       Date:  2008

10.  Relaxin protects astrocytes from hypoxia in vitro.

Authors:  Jordan M Willcox; Alastair J S Summerlee
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.